Abstract: Devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood. The pro-inflammatory cytokines can be freely circulating in the blood as well as cytokines that are transported within or bound to the surface of particles collectively referred to as CytoVesicles while simultaneously adsorbing toxins and pathogens from blood and blood plasma. A plasma separation column with binding, capture and adsorbent components optimize the removal of cytokines and CytoVesicles from blood while minimizing the removal of essential blood elements. Adsorbent components are incorporated within the extra-lumen space, outside of the plasma fiber walls and within the outer shell of the column and can include activated carbon, ion exchange resins and non-ionic exchange resins. The resulting devices, systems and methods alleviate the symptoms or severity of a wide range of disease conditions associated with an abnormal production or dysregulation of pro-inflammatory cytokines.

Abstract: The device described herein converges the plasma separation function of a hollow-fiber plasmapheresis device with a formulation or cocktail of two or more adsorbent components housed in the extra-lumen space (outside the fiber walls, yet inside the outer shell of the plasmapheresis device) to optimize the adsorption of viral pathogens, shed viral proteins and viral exosomes (collectively known as the Viral Targets) in a low-shear force environment without interacting with blood cells.

Abstract: Despite therapeutic advances in the field of oncology, treatment toxicity, drug resistance, and inadequate tumor site delivery restrict the benefit of cancer chemotherapy regimens. Disclosed are extracorporeal devices comprising adsorbent components that are suitable for treating a subject prior to and following administration of a dose of a chemotherapy drug, wherein the devices are configured to remove circulating factors comprising a chemotherapy drug from blood or plasma. Also disclosed herein are methods of reducing the bloodstream presence of circulating factors that mediate drug resistance, drug toxicity, and cancer metastasis, wherein circulating factors include without limitation, tumor-derived and/or chemotherapy-induced extracellular vesicles or exosomes.

Abstract: The device described herein converges the plasma separation function of a hollow-fiber plasmapheresis device with a formulation or cocktail of two or more adsorbent components housed in the extra-lumen space (outside the fiber walls, yet inside the outer shell of the plasmapheresis device) to optimize the adsorption of viral pathogens, shed viral proteins and viral exosomes (collectively known as the Viral Targets) in a low-shear force environment without interacting with blood cells.

Abstract: Devices, systems and methods for the broad-spectrum reduction of pro-inflammatory cytokines in blood. The pro-inflammatory cytokines can be freely circulating in the blood as well as cytokines that are transported within or bound to the surface of particles collectively referred to as CytoVesicles while simultaneously adsorbing toxins and pathogens from blood and blood plasma. A plasma separation column with binding, capture and adsorbent components optimize the removal of cytokines and CytoVesicles from blood while minimizing the removal of essential blood elements. Adsorbent components are incorporated within the extra-lumen space, outside of the plasma fiber walls and within the outer shell of the column and can include activated carbon, ion exchange resins and non-ionic exchange resins. The resulting devices, systems and methods alleviate the symptoms or severity of a wide range of disease conditions associated with an abnormal production or dysregulation of pro-inflammatory cytokines.

Abstract: The present invention relates to a method for using lectins that bind to pathogens having surface glycoproteins or fragments thereof which contain glycoproteins, to remove them from infected blood or plasma or other fluids in an extracorporeal setting. Accordingly, the present invention provides a methods and devices for reducing viral load or plaque forming units in blood or plasma from one or more infected individuals. A preferred embodiment of the method comprises passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are disposed proximate to the membrane, collecting pass-through blood or plasma and optionally reinfusing the pass-through blood or plasma into the individual. Additionally, the present invention provides a methods and devices for the reduction of plaque forming units, cleared more rapidly and more efficiently than overall viral load.

Abstract: The present technology relates to methods and systems for the removal of pathogens and fragments thereof in hemodialysis patients. In particular, methods and systems are described where lectins can be used to remove the Hepatitis C virus and fragments thereof in hemodialysis patients, and to provide a sustained reduction in viral load.

Abstract: The present invention relates to a method for using lectins that bind to pathogens having surface glycoproteins or fragments thereof which contain glycoproteins, to remove them from infected blood or plasma or other fluids in an extracorporeal setting. Accordingly, the present invention provides a methods and devices for reducing viral load or plaque forming units in blood or plasma from one or more infected individuals. A preferred embodiment of the method comprises passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are disposed proximate to the membrane, collecting pass-through blood or plasma and optionally reinfusing the pass-through blood or plasma into the individual. Additionally, the present invention provides a methods and devices for the reduction of plaque forming units, cleared more rapidly and more efficiently than overall viral load.

Abstract: Embodiments of the present invention relate to enhanced antiviral therapy methods, devices, and kits for treating viral infections. The disclosed enhanced antiviral therapy methods, devices, and kits enhance the efficacy of an antiviral therapy by administering a lectin affinity hemodialysis treatment to an individual suffering from viral infection in combination with the antiviral therapy.